Article

Polo-like kinase 4 (Plk4) potentiates <i>anoikis</i> -resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotype

2022-12-19

Abstract excerpt

Polo-like kinase 4 (Plk4), the major regulator of centriole biogenesis, has emerged as a putative therapeutic target in cancer due to its abnormal expression in human carcinomas, leading to centrosome number deregulation, mitotic defects and chromosomal instability. Moreover, Plk4 deregulation promotes tumor growth and metastasis in mouse models and is significantly associated with poor patient prognosis. Here, we...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: deecd0f0-36eb-58c8-a24d-77d0da0ad862
DOI: 10.1101/2022.12.16.520613

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Polo-like kinase 4 (Plk4) potentiates <i>anoikis</i> -resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotypeDOI 10.1101/2022.12.16.520613Read

Polo-like kinase 4 (Plk4) potentiates anoikis-resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotype.Semantic proximity Read

Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer ManagementSemantic proximity Read

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapySemantic proximity Read

Plk1 overexpression induces chromosomal instability and suppresses tumor developmentSemantic proximity Read

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisSemantic proximity Read

PLK4: a link between centriole biogenesis and cancerSemantic proximity Read

Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian CancerSemantic proximity Read

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeuticsSemantic proximity Read

Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in OncologySemantic proximity Read

Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcom.Semantic proximity Read

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read